SlideShare a Scribd company logo
Bioterrorism
Dr Rikin Hasnani
 Introduction
 History
 CDC classification
 Potential agents of bioterrorism
 Role of Public Health system in bioterrorism attack
Introduction
 Bioterrorism involves the deliberate release of viruses, bacteria, or their by-
products (e.g., toxin) to cause morbidity and mortality in humans, animals, or
plants.
 All bioterrorism agents are naturally occurring organisms or toxins that can cause
sporadic disease under natural circumstances, but on occasion, medical
manipulation has been attempted to increase resistance to antibiotics or increase
organism virulence.
 Bioterrorism is an attractive weapon because biological agents are relatively easy
and inexpensive to obtain, can be easily disseminated, and can cause widespread
fear and panic beyond the actual physical damage.
Key Features of Biologic Agents Used as
Bioweapons
 High morbidity and mortality
 Potential for person-to-person spread
 Low infective dose and highly infectious by aerosol
 Lack of rapid diagnostic capability
 Lack of universally available effective vaccine
 Potential to cause anxiety
 Availability of pathogen and feasibility of production
 Environmental stability
 Database of prior research and development
 Potential to be “weaponized”
Bioterrorism
History
Bioterrorism
Bioterrorism
Classification
 Centers for Disease Control and Prevention (CDC) classifies potential
biologic threats into three categories: A, B, and C
 Category A agents are the highest-priority pathogens:
 can be easily disseminated or transmitted from person to person
 result in high mortality rates
 have the potential for major public health impact
 might cause public panic and social disruption
 require special action for public health preparedness
Category A agents
 Anthrax (Bacillus anthracis)
 Botulism (Clostridium botulinum toxin)
 Plague (Yersinia pestis)
 Smallpox (Variola major)
 Tularemia (Francisella tularensis)
Viral hemorrhagic fevers:
 Arenaviruses: Lassa, New World (Machupo, Junin, Guanarito, and Sabia)
 Bunyaviridae: Crimean Congo, Rift Valley
 Filoviridae: Ebola, Marburg
 Flaviviridae: Yellow fever; Omsk fever; Kyasanur Forest
 Category B agents include those that are moderately easy to disseminate, result in
moderate morbidity rates and low mortality rates, and require specifically
enhanced diagnostic capacity
Category B Agents
 PULMONARY AGENTS
 Glanders (Burkholderia mallei)
 Melioidosis (Burkholderia pseudomallei)
 Psittacosis (Chlamydophila psittaci)
 Q fever (Coxiella burnetii)
 Ricin toxin from Ricinus communis (castor beans)
 NONPULMONARY AGENTS
 Brucellosis (Brucella species)
 Epsilon toxin of Clostridium perfringens
 Food safety threats (e.g., Salmonella species, Escherichia coli
 O157 : H7, Shigella)
 Staphylococcal enterotoxin B
Category C Agents
 These agents have the future potential for engineering for easy dissemination or
high mortality.
 Influenza (novel strain)
 Nipah virus
 Typhus disease (Rickettsia prowazekii)
 Viral encephalitis (alphaviruses [e.g., Venezuelan equine
 encephalitis, eastern equine encephalitis, western equine
 encephalitis])
 Water safety threats (e.g., Vibrio cholerae, Cryptosporidium
 parvum)
Anthrax
 Anthrax is caused by a sporulating gram-positive rod, Bacillus anthracis
 Human disease largely occurs through contact with animal products, such as
animal skins, where the bacillus form converts back to the spore form.
 In 2001, however, 22 cases of anthrax occurred in the United States as an act of
bioterrorism through the postal system, placing anthrax on the forefront of
bioterrorism.
 Disease occurs when the spore form is introduced subcutaneously or via inhalation,
becomes the vegetative (bacillus) form, and starts replication. Endotoxin secretion,
along with a thick capsule that avoids phagocytosis, leads to local spread, edema,
hemorrhage, and tissue necrosis.
 The anthrax capsule, edema factor toxin, and lethal factor toxin act in concert to
drive disease.
Bioterrorism
Clinical features
 1) Inhalational anthrax :
 Incubation period 1-7days
 Within 24 hours, disease rapidly progresses with the development of respiratory
failure, hemorrhagic mediastinitis, necrotizing pneumonia, shock, multiorgan failure
and death.
 The development of shock and multiorgan failure can occur rapidly, and along
with the hemorrhagic mediastinitis, is the clinical hallmark of anthrax.
 Cutaneous anthrax has an incubation period of 7 to 14 days after inoculation of
spores into the subcutaneous space.
 Initially a small, painless papule develops that can be pruritic.
 The papule enlarges and develops a central vesicle, followed by erosion into a
painless black eschar.
 Edema of surrounding tissues, and regional lymphadenopathy is seen along with
systemic symptoms of fever and malaise.
 The hands, arms, face, and neck are the most common areas affected.
 Gastrointestinal anthrax occurs after consumption of undercooked meats of
infected animals.
 Bowel edema occurs, followed by mesenteric lymphadenitis and necrosis, with
rapid progression to shock and death.
Bioterrorism
Management
 Diagnosis is made by culture of the blood, sputum, pleural fluid, cerebrospinal
fluid, or skin.
 Treatment :
 Ciprofloxacin
 Doxycyclin
Small pox
 Variola virus is the causative agent of smallpox and is a member of the Poxviridae
family.
 Smallpox was eradicated worldwide in 1977 but now has regained interest as a
potential bioterrorism agent.
 Due to an increasing unvaccinated population along with its contagiousness and
ability to be transmitted by aerosol, smallpox is a CDC category A bioterrorism
agent.
 Only two stockpiles of the virus remain (at the CDC and the Russian State Research
Center) for continued research.
Five main clinical categories:
 ordinary, - macule , papule, vesicle, pustule
 modified, more rapid but less severe
 flat,
 hemorrhagic,more common in pregnant female
 Variola sine eruptione
Variola: first and second day of rash (4th-5th day
of fever)
Variola: 4th day of rash
•For the first time-on
the fourth day of the
rash and the fifth day
of infectiousness, a
typical vesicular
appearance is seen
Variola major: drying rash (7-9 days)
•The rash is
becoming less
infectious
•Conjunctival
lesions are usually
benign and heal
completely
Variola major: confluent on day 7 of rash
Variola major: scabbing of rash: day 11
 Diagnosis is primarily clinical.
 RT PCR is awailable only at Centre for disease control.
 Treatment is supportive, with some evidence that cidofivir has activity in animal
model.
Plague
 Yersinia pestis is the etiologic agent of plague and has caused a number of
pandemics throughout human history.
 Transmission to humans occurs by rodent-infected flea bites, infected animal
scratches or bites, exposure to infected humans, and bioterrorism.
Bioterrorism
Clinical features
 In bubonic plague, a sudden onset of fevers, chills, and headache is followed by
pain and swelling in the regional lymph nodes proximal to the site of the bite or
scratch.
 This lymph node (bubo) is characterized by intense tenderness with erythema and
edema. Fluctuation test is negative.
 Septicemic plague occurs with acute fever followed by sepsis without the presence
of a bubo.
 Pneumonic plague , has short incubation period and rapidly develops ARDS
Bioterrorism
Management
 Diagnosis : clinical diagnosis is difficult
 Laboratory diagnosis is primarily by culture of the sputum or blood as Y. pestis
grows well on most laboratory media.
 Serology and rapid diagnostic testing by ELISA or PCR is also available but is used
primarily in field testing.
 Treatment :
 Streptomycin is drug of choice
 Gentamycin or doxycycline can also be used.
Tularemia
 Tularemia is caused by the gram-negative bacterium Francisella tularensis and is a
zoonotic disease, with humans as accidental hosts.
 Human infections occur by contact with ticks and flies, handling infected animals,
improperly prepared animal meat, animal scratches and bites, drinking
contaminated water, or aerosolization of the organism from the environment or in
bioterrorism.
 Human-to-human transmission does not occur.
Bioterrorism
Clinical features
 Six patterns of disease
 Ulceroglandular,
 Glandular,
 Pneumonic,
 Oropharyneal,
 Oculoglandular
Bioterrorism
Management
 Diagnosis : Bacteria is very difficult to grow on culture media.
 Diagnosis is made by ELISA or histologic examination showing gram-negative
intracellular organisms.
 X ray shows patchy opacities bilaterally,and hilar adenopathy.
 Pleural effusions and a miliary pattern can alsooccur, although this is less common.
Mediastinal adenopathy is seen rarely.
 Treatment : Genatamycin is drug of choice
 Doxycyclin and ciprofloaxacin are 2nd choice
Glanders
 It is caused by Burkholderia mallei
 It is primary a disease of horses. Human is infected due to contact or droplet
infection.
 Clinical features : usually acute or chronic skin infection
 Droplet infection can cause pneumonia and sepsis rapidly
 Usually misclassified on culture as it is a rare disease.
 Treatment : Imipenem is the drug of choice
3rd generation cephalosporin, ciorofloxacin are alternative
Melioidosis
 Caused by Burkholderia pseudomallei.
 Soil and water are natural reservoir
 Spread to human by direct contact or inhalation
 In bioterrorism aerosolisation will lead to pneumonia.
 Most patients develop sepsis and MODS rapidly.
 Diagnosis is by culture
 Treatment : imipenem or 3rd gen cephalsoprin in acute condition followed by
20day treatment with doxycycline or cotrimoxazole.
Psittacosis
 Psittacosis is caused by Chlamydophila psittaci, an intracellular bacterium routinely
associated with birds such as parrots, cockatiels, and canaries.
 Intentional aerosolization would lead to multiple cases of nonspecific “atypical
pneumonia” with cough, fever, and headache.
 Diagnosis is by ELISA , difficult to grow on cultures
 Treatment is macrolide or doxycycline or ciprofloxacin
Q Fever
 Q fever is a zoonotic disease caused by Coxiella burnetii.
 Cattle, sheep, and goats are the primary reservoirs
 It does not cause clinical disease in animals, bacteria is found in milk, urine, feces,
amniotic fluids, and placenta.
 Infection by droplet spread.
 Clinical features : high fevers (> 104° F), severe headache, myalgia, sore throat,
nonproductive cough, nausea, vomiting, diarrhea, abdominal pain, and chest pain.
 Fever usually lasts for 1 to 2 weeks.
 Thirty percent to 50% of patients with symptomatic infection will develop
pneumonia
 Endocarditis, chronic Q fever(>6 months) are rare complications.
 Diagnosis is made by indirect immunoflouroscence assay.
 Doxycycline 100 mg twice daily for 15 to 21 days is the treatment of choice for Q
fever.
Role of physician
 The recognition of a bioterrorism event versus a naturally occurring infection relies
on a high suspicion on behalf of the clinician.
 However it is difficult in initial stages of disease when symptoms are non specific.
 a systematic approach is advocated initially in all febrile respiratory illnesses, with
suspicion and should contact public health when specific clinical findings or
epidemiologic features are detected that lead the clinician to suspect a
bioterrorism or emerging infectious disease event
Bioterrorism
Role Of Public Health System
Being Prepared
 Education of medical community
 Education of public
 Training of special response teams
 Participation in exercises for different scenarios
 Development of communication systems
 Development of interagency protocols
Initial Response to BT Induced Disease
 Early detection through surveillance/ rapid assessment of reports
 Mobilize laboratory
 Rapid confirmation of agent, site, initial at-risk population, prophylaxis and/or
treatment
 Alert medical community, ERs, labs
 Implement disease specific plans (e.g. Smallpox)
 Determine resource needs and possible quarantine
 Coordinate with partner agencies (local/state/national
Continued Response to BT Induced Diseases
 Closely monitor communication network for new information
 Provide, accurate, timely information to public
 Continue epidemiologic investigation to refine at risk population
 Assess environmental contamination
 Provide or coordinate testing/ prophylaxis/ treatment to at-risk population
 Access biological stockpiles as necessary
Thank you

More Related Content

PPSX
Bioterrorism 29.03.2020
PPT
Bioterrorism
PPTX
Bioterrorism
PPT
Bioterrorism: History, Advantages and Weaponry
PPTX
Bioterrorism
PPTX
Bioterrorism (2)
PPTX
Bioterrorism
PPTX
BIOTERRORISM
Bioterrorism 29.03.2020
Bioterrorism
Bioterrorism
Bioterrorism: History, Advantages and Weaponry
Bioterrorism
Bioterrorism (2)
Bioterrorism
BIOTERRORISM

What's hot (20)

PPTX
Zika virus
PPSX
Salmonellosis
PPTX
PPTX
Bioterrorism
PPT
1.introduction and history of biological warfare agents
PPTX
Lpa and Genexpert/CBNAAT/Xpert MTB/Rif
PPT
BIOTERRORISM SKG.ppt
PPTX
Zoonotic disease
PPTX
Anthrax
PPTX
Bioterrorism 2018
PPTX
Cytomegalovirus
PPTX
PPTX
Immunosurveillance,
PPTX
Emerging and reemerging infectious diseases
PPTX
Dermatomycosis
PPTX
Histoplasmosis
PPTX
Resistant tb
PDF
Entomology Spotters
PPTX
Emerging and re emerging diseases
PPTX
Laboratory diagnosis of tuberculosis pract.
Zika virus
Salmonellosis
Bioterrorism
1.introduction and history of biological warfare agents
Lpa and Genexpert/CBNAAT/Xpert MTB/Rif
BIOTERRORISM SKG.ppt
Zoonotic disease
Anthrax
Bioterrorism 2018
Cytomegalovirus
Immunosurveillance,
Emerging and reemerging infectious diseases
Dermatomycosis
Histoplasmosis
Resistant tb
Entomology Spotters
Emerging and re emerging diseases
Laboratory diagnosis of tuberculosis pract.
Ad

Similar to Bioterrorism (20)

PPTX
bioterrorigggggggggggggggsm-170215073558.pptx
PPT
Bioterror Slide Show
PPTX
Bioterrorism
PPTX
Bioterrorism healey
PDF
PPT
Bioterror Slide Show
PPTX
Biological disaster tam 2014-12
PPT
Biological disasters
PDF
Infectious agents of bioterrorism handout
PPTX
infectious agents that might be used as biological weapon
PPT
Bioterror_120530.ppt
PPTX
Terrorism & clinical medicine.namal 1
PPTX
Biological_Warfare_An Overview of Threats, History, and Responses.pptx
PPTX
Biological_Warfare_An Overview of Threats, History, and Responses.pptx
PPTX
Infectious Diseaseeeeeesdr amirrrrr.pptx
PPT
Nurs 214.Bioterrorism
PPTX
Infectious Diseases.pptx
PPTX
Infectious Diseases.pptx
PDF
Bioterrorism_-_657_Khushi.pdf
PPT
Bioterrorism
bioterrorigggggggggggggggsm-170215073558.pptx
Bioterror Slide Show
Bioterrorism
Bioterrorism healey
Bioterror Slide Show
Biological disaster tam 2014-12
Biological disasters
Infectious agents of bioterrorism handout
infectious agents that might be used as biological weapon
Bioterror_120530.ppt
Terrorism & clinical medicine.namal 1
Biological_Warfare_An Overview of Threats, History, and Responses.pptx
Biological_Warfare_An Overview of Threats, History, and Responses.pptx
Infectious Diseaseeeeeesdr amirrrrr.pptx
Nurs 214.Bioterrorism
Infectious Diseases.pptx
Infectious Diseases.pptx
Bioterrorism_-_657_Khushi.pdf
Bioterrorism
Ad

More from Rikin Hasnani (18)

PPTX
Information Education Communication in RNTCP
PPTX
Immunohistochemistry in lung cancer
PPTX
Acute Respiratory Distress Syndrome
PPTX
Ct diffuse lung disease
PPTX
Ct chest pneumonias and neoplasms
PPTX
molecular biology and Target therapy in lung cancer
PPTX
Pulmonary thromboembolism
PPTX
Pulmonary artery Hypertension
PPTX
Obstructive sleep Apnea
PPTX
PPTX
Lung transplantation
PPTX
Lung in pancreatitis
PPTX
Eosinophillic pneumonia
PPTX
Endobronchial ultrasound - EBUS
PPTX
Chest x ray - basics
PPTX
Ct chest developmental anomalies , airways
PPTX
Ct Chest - Pleura
PPTX
Congenital Disorder of lung
Information Education Communication in RNTCP
Immunohistochemistry in lung cancer
Acute Respiratory Distress Syndrome
Ct diffuse lung disease
Ct chest pneumonias and neoplasms
molecular biology and Target therapy in lung cancer
Pulmonary thromboembolism
Pulmonary artery Hypertension
Obstructive sleep Apnea
Lung transplantation
Lung in pancreatitis
Eosinophillic pneumonia
Endobronchial ultrasound - EBUS
Chest x ray - basics
Ct chest developmental anomalies , airways
Ct Chest - Pleura
Congenital Disorder of lung

Recently uploaded (20)

PPT
Rheumatology Member of Royal College of Physicians.ppt
PDF
OSCE SERIES ( Questions & Answers ) - Set 5.pdf
PPTX
Cardiovascular - antihypertensive medical backgrounds
PPTX
Introduction to Medical Microbiology for 400L Medical Students
PDF
Lecture on Anesthesia for ENT surgery 2025pptx.pdf
PPTX
Radiation Dose Management for Patients in Medical Imaging- Avinesh Shrestha
PDF
Oral Aspect of Metabolic Disease_20250717_192438_0000.pdf
PDF
OSCE SERIES ( Questions & Answers ) - Set 3.pdf
PPTX
Neonate anatomy and physiology presentation
PDF
SEMEN PREPARATION TECHNIGUES FOR INTRAUTERINE INSEMINATION.pdf
PPT
Dermatology for member of royalcollege.ppt
PDF
Plant-Based Antimicrobials: A New Hope for Treating Diarrhea in HIV Patients...
PDF
The_EHRA_Book_of_Interventional Electrophysiology.pdf
DOCX
PEADIATRICS NOTES.docx lecture notes for medical students
PPTX
Human Reproduction: Anatomy, Physiology & Clinical Insights.pptx
PDF
Pharmaceutical Regulation -2024.pdf20205939
PPTX
preoerative assessment in anesthesia and critical care medicine
PPTX
Electrolyte Disturbance in Paediatric - Nitthi.pptx
PPT
nephrology MRCP - Member of Royal College of Physicians ppt
PPTX
MANAGEMENT SNAKE BITE IN THE TROPICALS.pptx
Rheumatology Member of Royal College of Physicians.ppt
OSCE SERIES ( Questions & Answers ) - Set 5.pdf
Cardiovascular - antihypertensive medical backgrounds
Introduction to Medical Microbiology for 400L Medical Students
Lecture on Anesthesia for ENT surgery 2025pptx.pdf
Radiation Dose Management for Patients in Medical Imaging- Avinesh Shrestha
Oral Aspect of Metabolic Disease_20250717_192438_0000.pdf
OSCE SERIES ( Questions & Answers ) - Set 3.pdf
Neonate anatomy and physiology presentation
SEMEN PREPARATION TECHNIGUES FOR INTRAUTERINE INSEMINATION.pdf
Dermatology for member of royalcollege.ppt
Plant-Based Antimicrobials: A New Hope for Treating Diarrhea in HIV Patients...
The_EHRA_Book_of_Interventional Electrophysiology.pdf
PEADIATRICS NOTES.docx lecture notes for medical students
Human Reproduction: Anatomy, Physiology & Clinical Insights.pptx
Pharmaceutical Regulation -2024.pdf20205939
preoerative assessment in anesthesia and critical care medicine
Electrolyte Disturbance in Paediatric - Nitthi.pptx
nephrology MRCP - Member of Royal College of Physicians ppt
MANAGEMENT SNAKE BITE IN THE TROPICALS.pptx

Bioterrorism

  • 2.  Introduction  History  CDC classification  Potential agents of bioterrorism  Role of Public Health system in bioterrorism attack
  • 3. Introduction  Bioterrorism involves the deliberate release of viruses, bacteria, or their by- products (e.g., toxin) to cause morbidity and mortality in humans, animals, or plants.  All bioterrorism agents are naturally occurring organisms or toxins that can cause sporadic disease under natural circumstances, but on occasion, medical manipulation has been attempted to increase resistance to antibiotics or increase organism virulence.  Bioterrorism is an attractive weapon because biological agents are relatively easy and inexpensive to obtain, can be easily disseminated, and can cause widespread fear and panic beyond the actual physical damage.
  • 4. Key Features of Biologic Agents Used as Bioweapons  High morbidity and mortality  Potential for person-to-person spread  Low infective dose and highly infectious by aerosol  Lack of rapid diagnostic capability  Lack of universally available effective vaccine  Potential to cause anxiety  Availability of pathogen and feasibility of production  Environmental stability  Database of prior research and development  Potential to be “weaponized”
  • 9. Classification  Centers for Disease Control and Prevention (CDC) classifies potential biologic threats into three categories: A, B, and C  Category A agents are the highest-priority pathogens:  can be easily disseminated or transmitted from person to person  result in high mortality rates  have the potential for major public health impact  might cause public panic and social disruption  require special action for public health preparedness
  • 10. Category A agents  Anthrax (Bacillus anthracis)  Botulism (Clostridium botulinum toxin)  Plague (Yersinia pestis)  Smallpox (Variola major)  Tularemia (Francisella tularensis) Viral hemorrhagic fevers:  Arenaviruses: Lassa, New World (Machupo, Junin, Guanarito, and Sabia)  Bunyaviridae: Crimean Congo, Rift Valley  Filoviridae: Ebola, Marburg  Flaviviridae: Yellow fever; Omsk fever; Kyasanur Forest
  • 11.  Category B agents include those that are moderately easy to disseminate, result in moderate morbidity rates and low mortality rates, and require specifically enhanced diagnostic capacity
  • 12. Category B Agents  PULMONARY AGENTS  Glanders (Burkholderia mallei)  Melioidosis (Burkholderia pseudomallei)  Psittacosis (Chlamydophila psittaci)  Q fever (Coxiella burnetii)  Ricin toxin from Ricinus communis (castor beans)  NONPULMONARY AGENTS  Brucellosis (Brucella species)  Epsilon toxin of Clostridium perfringens  Food safety threats (e.g., Salmonella species, Escherichia coli  O157 : H7, Shigella)  Staphylococcal enterotoxin B
  • 13. Category C Agents  These agents have the future potential for engineering for easy dissemination or high mortality.  Influenza (novel strain)  Nipah virus  Typhus disease (Rickettsia prowazekii)  Viral encephalitis (alphaviruses [e.g., Venezuelan equine  encephalitis, eastern equine encephalitis, western equine  encephalitis])  Water safety threats (e.g., Vibrio cholerae, Cryptosporidium  parvum)
  • 14. Anthrax  Anthrax is caused by a sporulating gram-positive rod, Bacillus anthracis  Human disease largely occurs through contact with animal products, such as animal skins, where the bacillus form converts back to the spore form.  In 2001, however, 22 cases of anthrax occurred in the United States as an act of bioterrorism through the postal system, placing anthrax on the forefront of bioterrorism.
  • 15.  Disease occurs when the spore form is introduced subcutaneously or via inhalation, becomes the vegetative (bacillus) form, and starts replication. Endotoxin secretion, along with a thick capsule that avoids phagocytosis, leads to local spread, edema, hemorrhage, and tissue necrosis.  The anthrax capsule, edema factor toxin, and lethal factor toxin act in concert to drive disease.
  • 17. Clinical features  1) Inhalational anthrax :  Incubation period 1-7days  Within 24 hours, disease rapidly progresses with the development of respiratory failure, hemorrhagic mediastinitis, necrotizing pneumonia, shock, multiorgan failure and death.  The development of shock and multiorgan failure can occur rapidly, and along with the hemorrhagic mediastinitis, is the clinical hallmark of anthrax.
  • 18.  Cutaneous anthrax has an incubation period of 7 to 14 days after inoculation of spores into the subcutaneous space.  Initially a small, painless papule develops that can be pruritic.  The papule enlarges and develops a central vesicle, followed by erosion into a painless black eschar.  Edema of surrounding tissues, and regional lymphadenopathy is seen along with systemic symptoms of fever and malaise.  The hands, arms, face, and neck are the most common areas affected.
  • 19.  Gastrointestinal anthrax occurs after consumption of undercooked meats of infected animals.  Bowel edema occurs, followed by mesenteric lymphadenitis and necrosis, with rapid progression to shock and death.
  • 21. Management  Diagnosis is made by culture of the blood, sputum, pleural fluid, cerebrospinal fluid, or skin.  Treatment :  Ciprofloxacin  Doxycyclin
  • 22. Small pox  Variola virus is the causative agent of smallpox and is a member of the Poxviridae family.  Smallpox was eradicated worldwide in 1977 but now has regained interest as a potential bioterrorism agent.  Due to an increasing unvaccinated population along with its contagiousness and ability to be transmitted by aerosol, smallpox is a CDC category A bioterrorism agent.  Only two stockpiles of the virus remain (at the CDC and the Russian State Research Center) for continued research.
  • 23. Five main clinical categories:  ordinary, - macule , papule, vesicle, pustule  modified, more rapid but less severe  flat,  hemorrhagic,more common in pregnant female  Variola sine eruptione
  • 24. Variola: first and second day of rash (4th-5th day of fever)
  • 25. Variola: 4th day of rash •For the first time-on the fourth day of the rash and the fifth day of infectiousness, a typical vesicular appearance is seen
  • 26. Variola major: drying rash (7-9 days) •The rash is becoming less infectious •Conjunctival lesions are usually benign and heal completely
  • 27. Variola major: confluent on day 7 of rash
  • 28. Variola major: scabbing of rash: day 11
  • 29.  Diagnosis is primarily clinical.  RT PCR is awailable only at Centre for disease control.  Treatment is supportive, with some evidence that cidofivir has activity in animal model.
  • 30. Plague  Yersinia pestis is the etiologic agent of plague and has caused a number of pandemics throughout human history.  Transmission to humans occurs by rodent-infected flea bites, infected animal scratches or bites, exposure to infected humans, and bioterrorism.
  • 32. Clinical features  In bubonic plague, a sudden onset of fevers, chills, and headache is followed by pain and swelling in the regional lymph nodes proximal to the site of the bite or scratch.  This lymph node (bubo) is characterized by intense tenderness with erythema and edema. Fluctuation test is negative.  Septicemic plague occurs with acute fever followed by sepsis without the presence of a bubo.  Pneumonic plague , has short incubation period and rapidly develops ARDS
  • 34. Management  Diagnosis : clinical diagnosis is difficult  Laboratory diagnosis is primarily by culture of the sputum or blood as Y. pestis grows well on most laboratory media.  Serology and rapid diagnostic testing by ELISA or PCR is also available but is used primarily in field testing.  Treatment :  Streptomycin is drug of choice  Gentamycin or doxycycline can also be used.
  • 35. Tularemia  Tularemia is caused by the gram-negative bacterium Francisella tularensis and is a zoonotic disease, with humans as accidental hosts.  Human infections occur by contact with ticks and flies, handling infected animals, improperly prepared animal meat, animal scratches and bites, drinking contaminated water, or aerosolization of the organism from the environment or in bioterrorism.  Human-to-human transmission does not occur.
  • 37. Clinical features  Six patterns of disease  Ulceroglandular,  Glandular,  Pneumonic,  Oropharyneal,  Oculoglandular
  • 39. Management  Diagnosis : Bacteria is very difficult to grow on culture media.  Diagnosis is made by ELISA or histologic examination showing gram-negative intracellular organisms.  X ray shows patchy opacities bilaterally,and hilar adenopathy.  Pleural effusions and a miliary pattern can alsooccur, although this is less common. Mediastinal adenopathy is seen rarely.  Treatment : Genatamycin is drug of choice  Doxycyclin and ciprofloaxacin are 2nd choice
  • 40. Glanders  It is caused by Burkholderia mallei  It is primary a disease of horses. Human is infected due to contact or droplet infection.  Clinical features : usually acute or chronic skin infection  Droplet infection can cause pneumonia and sepsis rapidly  Usually misclassified on culture as it is a rare disease.  Treatment : Imipenem is the drug of choice 3rd generation cephalosporin, ciorofloxacin are alternative
  • 41. Melioidosis  Caused by Burkholderia pseudomallei.  Soil and water are natural reservoir  Spread to human by direct contact or inhalation  In bioterrorism aerosolisation will lead to pneumonia.  Most patients develop sepsis and MODS rapidly.  Diagnosis is by culture  Treatment : imipenem or 3rd gen cephalsoprin in acute condition followed by 20day treatment with doxycycline or cotrimoxazole.
  • 42. Psittacosis  Psittacosis is caused by Chlamydophila psittaci, an intracellular bacterium routinely associated with birds such as parrots, cockatiels, and canaries.  Intentional aerosolization would lead to multiple cases of nonspecific “atypical pneumonia” with cough, fever, and headache.  Diagnosis is by ELISA , difficult to grow on cultures  Treatment is macrolide or doxycycline or ciprofloxacin
  • 43. Q Fever  Q fever is a zoonotic disease caused by Coxiella burnetii.  Cattle, sheep, and goats are the primary reservoirs  It does not cause clinical disease in animals, bacteria is found in milk, urine, feces, amniotic fluids, and placenta.  Infection by droplet spread.  Clinical features : high fevers (> 104° F), severe headache, myalgia, sore throat, nonproductive cough, nausea, vomiting, diarrhea, abdominal pain, and chest pain.  Fever usually lasts for 1 to 2 weeks.  Thirty percent to 50% of patients with symptomatic infection will develop pneumonia
  • 44.  Endocarditis, chronic Q fever(>6 months) are rare complications.  Diagnosis is made by indirect immunoflouroscence assay.  Doxycycline 100 mg twice daily for 15 to 21 days is the treatment of choice for Q fever.
  • 45. Role of physician  The recognition of a bioterrorism event versus a naturally occurring infection relies on a high suspicion on behalf of the clinician.  However it is difficult in initial stages of disease when symptoms are non specific.  a systematic approach is advocated initially in all febrile respiratory illnesses, with suspicion and should contact public health when specific clinical findings or epidemiologic features are detected that lead the clinician to suspect a bioterrorism or emerging infectious disease event
  • 47. Role Of Public Health System Being Prepared  Education of medical community  Education of public  Training of special response teams  Participation in exercises for different scenarios  Development of communication systems  Development of interagency protocols
  • 48. Initial Response to BT Induced Disease  Early detection through surveillance/ rapid assessment of reports  Mobilize laboratory  Rapid confirmation of agent, site, initial at-risk population, prophylaxis and/or treatment  Alert medical community, ERs, labs  Implement disease specific plans (e.g. Smallpox)  Determine resource needs and possible quarantine  Coordinate with partner agencies (local/state/national
  • 49. Continued Response to BT Induced Diseases  Closely monitor communication network for new information  Provide, accurate, timely information to public  Continue epidemiologic investigation to refine at risk population  Assess environmental contamination  Provide or coordinate testing/ prophylaxis/ treatment to at-risk population  Access biological stockpiles as necessary